OncoMatch/Clinical Trials/NCT05296070
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Is NCT05296070 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Loncastuximab tesirine 150 µg/Kg and Loncastuximab tesirine 75µg/Kg for marginal zone lymphoma.
Treatment: Loncastuximab tesirine 150 µg/Kg · Loncastuximab tesirine 75µg/Kg — The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 prior anti-CD20 antibody therapy
including at least 1 anti-CD20 antibody (cluster of differentiation antigen 20) (either as monotherapy or in combination as chemoimmunotherapy)
Excluded: CD19 prior anti-CD19 therapy
Previous treatment with anti CD19 (cluster of differentiation antigen 19 ) approaches
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody
including at least 1 anti-CD20 antibody (cluster of differentiation antigen 20) (either as monotherapy or in combination as chemoimmunotherapy), with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen
Cannot have received: anti-CD19 therapy
Previous treatment with anti CD19 (cluster of differentiation antigen 19 ) approaches
Cannot have received: allogeneic stem cell transplant
Exception: within the last 6 months
Allogeneic stem cell transplant within the last 6 months
Cannot have received: autologous stem cell transplant
Exception: within the last 3 months
autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelet count ≥ 50 × 10^9/L
Kidney function
Calculated creatinine clearance ≥ 45 mL/min by Cockcroft-Gault or eGFR ≥ 45 mL/min/1.73 m2
Liver function
Total bilirubin ≤ 1.5 × ULN (subjects with Gilbert's syndrome eligible if indirect bilirubin elevated); ALT/AST ≤ 3.0 ULN or ≤ 5 × ULN with liver involvement
Adequate hematologic, hepatic, and renal function tested within 6 weeks prior to the start of therapy (values must not be achieved with growth factors): ANC ≥ 1.0 × 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelet count ≥ 50 × 10^9/L; Total bilirubin ≤ 1.5 × ULN (subjects with Gilbert's syndrome eligible if indirect bilirubin elevated); ALT/AST ≤ 3.0 ULN or ≤ 5 × ULN with liver involvement; Calculated creatinine clearance ≥ 45 mL/min by Cockcroft-Gault or eGFR ≥ 45 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- University of Miami · Miami, Florida
- Emory University · Atlanta, Georgia
- Vanderbilt University · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify